



Kevin Ali

Chief Executive Officer and Board member

Kevin helped lead the formation of Organon, a spin-off from Merck & Co., known as MSD outside the U.S. and Canada, with a mission to deliver impactful medicines and solutions.

Under Kevin's leadership, Organon has made significant progress in establishing itself as the world's leading women's health company, serving patients in over 140 markets.

Before Organon, Kevin spent more than three decades at Merck, where he held a variety of leadership roles. He served as president of Merck's international business, responsible for commercial markets outside the U.S. Under his leadership, the business was a significant driver of Merck's growth. Earlier in his career, Kevin was the president of the emerging markets region, where he transformed the performance of many countries for sustained growth.

Kevin serves as Chair of the U.S. Chamber of Commerce's China Center Advisory Board and was the 2023 co-chair of the private sector host committee for the Asia-Pacific Economic Cooperation (APEC). He is also a signatory to the United Nations Women's Empowerment Principles, the UN's Global Compact CEO Water Mandate, and several other initiatives that advance health access for women and families. Under Kevin's leadership, Organon has been widely recognized as a purpose-led company and has been named to Newsweek's 2023 Most Responsible Companies. Kevin has also received accolades from media including being named to the Healthcare Power List 2023 and a "CEO Trailblazer" for his commitment to advancing innovation in women's health.

Kevin has an M.B.A. from Santa Clara University and a B.A. from the University of California, Berkeley.